Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy
Pacira BioSciences (NASDAQ: PCRX) will present new 3-year clinical data for investigational PCRX-201 (enekinragene inzadenovec), a high-capacity adenovirus serotype 5 gene therapy for knee osteoarthritis, at ACR Convergence 2025 in Chicago.
The poster reports sustained improvements in pain and function from a Phase 1 trial and lists safety observations; a Phase 2 ASCEND study is currently underway. Presentation by Stanley Cohen, MD is scheduled for Tuesday, October 28, 10:30 a.m.–12:30 p.m. CT.
Pacira BioSciences (NASDAQ: PCRX) presenterà nuovi dati clinici triennali per l'investigational PCRX-201 (enekinragene inzadenovec), una terapia genica ad alta capacità basata su adenovirus di tipo 5 per l'osteoartrite del ginocchio, all'ACR Convergence 2025 a Chicago.
Il poster riporta miglioramenti sostenuti nel dolore e nella funzione da uno studio di Fase 1 e elenca osservazioni di sicurezza; uno studio di Fase 2 ASCEND è attualmente in corso. La presentazione di Stanley Cohen, MD è prevista per martedì, 28 ottobre, dalle 10:30 alle 12:30 CT.
Pacira BioSciences (NASDAQ: PCRX) presentará nuevos datos clínicos de 3 años para la investigacional PCRX-201 (enekinragene inzadenovec), una terapia génica de alto rendimiento basada en un adenovirus tipo 5 para la osteoarthrosis de rodilla, en ACR Convergence 2025 en Chicago.
El póster informa mejoras sostenidas en el dolor y la función de un ensayo de Fase 1 y enumera observaciones de seguridad; un estudio de Fase 2 ASCEND está actualmente en curso. La presentación por Stanley Cohen, MD está programada para martes, 28 de octubre, de 10:30 a.m. a 12:30 p.m. CT.
Pacira BioSciences (NASDAQ: PCRX)는 암시된 PCRX-201 (enekinragene inzadenovec)에 대한 3년 임상 데이터를 제시할 예정이며, 이는 무릎 골관절염을 위한 고용량 아데노바이러스 5형 기반의 유전자 치료제입니다. 이 발표는 시카고에서 열리는 ACR Convergence 2025에서 이루어질 예정입니다.
포스터는 Fase 1 시험에서 통증과 기능의 지속적인 개선과 안전성 관찰을 보고하며, 현재 2상 ASCEND 연구가 진행 중입니다. Stanley Cohen, MD의 발표는 2025년 10월 28일 화요일, 현지 시각 오전 10:30–오전 12:30에 예정되어 있습니다.
Pacira BioSciences (NASDAQ: PCRX) présentera de nouvelles données cliniques sur 3 ans pour l'investigational PCRX-201 (enekinragene inzadenovec), une thérapie génique à haute capacité utilisant un adénovirus de type 5 pour l'ostéoarthrite du genou, lors de l'ACR Convergence 2025 à Chicago.
L'affiche rapporte des améliorations soutenues de la douleur et de la fonction issues d'un essai de Phase 1 et répertorie des observations de sécurité; une étude de Phase 2 ASCEND est actuellement en cours. La présentation par Stanley Cohen, MD est prévue pour mardi 28 octobre, de 10 h 30 à 12 h 30 CT.
Pacira BioSciences (NASDAQ: PCRX) wird neue 3-Jahres-Daten zu dem in der Erprobung befindlichen PCRX-201 (enekinragene inzadenovec), einer Hochkapazitäts-Gentherapie basierend auf dem Adenovirus Serotyp 5, bei Kniegelenkarthrose, auf der ACR Convergence 2025 in Chicago vorstellen.
Das Poster berichtet über anhaltende Verbesserungen von Schmerz und Funktion aus einer Phase-1-Studie und listet Sicherheitsbeobachtungen auf; eine Phase-2-ASCEND-Studie ist derzeit im Gange. Die Präsentation von Stanley Cohen, MD ist für Dienstag, 28. Oktober, 10:30–12:30 Uhr CT vorgesehen.
Pacira BioSciences (NASDAQ: PCRX) ستعرض بيانات سريرية جديدة لمدة 3 سنوات لـ PCRX-201 (enekinragene inzadenovec)، وهي علاج جيني عالي القدرة يعتمد على فيروس الأدينو النوع 5 لعلاج التهاب مفاصل الركبة، في ACR Convergence 2025 في شيكاغو.
يورد الملصق تحسنات مستمرة في الألم والوظيفة من تجربة المرحلة 1 ويعرض ملاحظات السلامة؛ وتجرى حالياً تجربة من المرحلة 2 ASCEND. العرض التقديمي من ستانلي كوهين، د. م سيكون مقررًا لـ الثلاثاء، 28 أكتوبر، من 10:30 صباحاً إلى 12:30 ظهراً بتوقيت CT.
Pacira BioSciences (NASDAQ: PCRX) 将在芝加哥的 ACR Convergence 2025 上展示关于研究阶段的 PCRX-201 (enekinragene inzadenovec) 的新三年临床数据，这是一种用于膝盖骨关节炎的高载量 5 型腺病毒基因治疗。
该海报报告了来自一项 1 期试验的疼痛和功能的持续改善，并列出安全性观察结果；一项 2 期 ASCEND 研究正在进行中。Stanley Cohen, MD 的演讲计划在 10 月 28 日（星期二），CT 时间 10:30 a.m.–12:30 p.m.。
- None.
- None.
-- Poster to be presented at American College of Rheumatology Convergence 2025 –
BRISBANE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that new data from its Phase 1 clinical trial evaluating PCRX-201 (enekinragene inzadenovec), a novel gene therapy candidate for osteoarthritis of the knee, will be presented at the American College of Rheumatology (ACR) Convergence 2025 meeting, taking place from October 24-29 in Chicago, Il.
A Phase 2 study of PCRX-201 (the ASCEND study) for the treatment of osteoarthritis of the knee is currently underway.
Presentation Title: PCRX-201 High-Capacity Adenovirus Serotype 5 Gene Therapy Demonstrates Sustained Clinical Efficacy and Safety in Patients with Knee Osteoarthritis
Presented By: Stanley Cohen, MD, Co-Medical Director, Metroplex Clinical Research Center, Dallas, TX
Date & Time: Tuesday, October 28, 10:30 a.m. – 12:30 p.m. CT
About PCRX-201 (enekinragene inzadenovec)
PCRX-201 (enekinragene inzadenovec) features an innovative design based on the company’s proprietary high-capacity adenovirus vector platform. It is currently being studied in the fundamental, underlying chronic inflammatory processes that contribute to “wear and tear” over time in osteoarthritis of the knee, a condition that affects nearly 15 million individuals in the U.S. today.
In November 2024, Pacira reported promising data from a Phase 1 study of 72 patients in which PCRX-201 provided sustained improvements in knee pain, stiffness, and function through two years following local administration, with a well-tolerated safety profile. PCRX-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration and Advanced Therapy Medicinal Products (ATMP) designation from the European Medicines Agency. PCRX-201 is the first gene therapy to achieve these clinical results and earn these regulatory designations in osteoarthritis of the knee – a testament to its promise and potential.
About the High-capacity Adenovirus Vector Platform
In February 2025, in support of the company’s ‘5x30’ growth strategy, Pacira acquired GQ Bio Therapeutics GmbH (GQ Bio) and its novel high-capacity adenovirus (HCAd) vector gene therapy vector platform. This platform solves many of the challenges in the field of gene therapy that have prevented its utilization in treating common diseases, such as osteoarthritis.
Key features include:
- The HCAd vector is much more efficient at delivering genes into cells compared to many other gene therapies that rely on adenovirus associated virus, or AAV, vectors. As a result, the desired effect can be achieved with much smaller doses.
- The vector used in the HCAd platform can carry up to 30,000 base pairs of DNA, which enables gene therapy with multiple or larger genes compared to AAV vectors.
- Genetic medicines based on the HCAd platform can be administered locally and have the potential for redosing at therapeutically appropriate intervals.
- Lower dose levels and efficient delivery of genes into cells means that thousands of doses can be produced in a single batch. As a result, therapies built on the HCAd platform are expected to have a commercially attractive and viable cost of goods profile.
Beyond PCRX-201 and other product candidates in preclinical development, the company has identified numerous well-validated cytokines that could also be the basis for locally administered genetic therapies using the HCAd platform.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel, locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.
Investor Contact: Susan Mesco, (973) 451-4030 susan.mesco@pacira.com Media Contact: Kim Hamilton, (908) 721-7067 kim.hamilton@pacira.com
FAQ
What data will Pacira (PCRX) present for PCRX-201 at ACR Convergence 2025?
When and where will Pacira (PCRX) present PCRX-201 results at ACR Convergence 2025?
Who is presenting Pacira's (PCRX) PCRX-201 poster at ACR Convergence 2025?
What is the development status of PCRX-201 (enekinragene inzadenovec) for knee osteoarthritis?
Does the ACR presentation for PCRX-201 include safety data?
